Iroko Pharmaceuticals, LLC

President and Chief Executive Officer

John Vavricka has held numerous executive positions in sales, marketing, and research & development in biotech & pharmaceutical companies, both global and locally operating companies.

Mr. Vavricka was Vice President, Commercial Operations (North America and Europe) at Chiron Vaccines, the fifth-largest vaccine company worldwide. There he established the North American vaccine headquarters, being tasked with site selection; construction; and the hiring of marketing, sales, public policy, and government relations personnel. Upon Chiron's merger with Novartis, Mr. Vavricka facilitated Chiron's integration and developed market expansion strategy for the new Novartis Vaccines.

Prior to joining Chiron, Mr. Vavricka was with GlaxoSmithKline Pharmaceuticals, where he served as Vice President, Marketing. Before that, he held numerous positions of increasing responsibility at SmithKline Beecham Pharmaceuticals, lastly as Regional Vice President, Sales.

Chief Financial Officer

Fred Krieger has spent most his career directing various financial aspects of leading pharmaceutical companies. Prior to joining Iroko Pharmaceuticals, Mr. Krieger spent six years as Vice President, Financial Control, Planning and Reporting, at GlaxoSmithKline Pharmaceuticals Research & Development. There he directed the R&D accounting, consolidation, and reporting process, and was responsible for the overall budgeting and three-year planning process for R&D.

Mr. Krieger formerly held positions of increasing responsibility at SmithKline Beecham Pharmaceuticals, including positions in Philadelphia and London. For a number of years Mr. Krieger directly supported the Chief Executive Officer. He holds BBA and MBA degrees and is a Certified Public Accountant.

Senior Vice President of Commercial Operations, Europe

Humphrey Harte is an international pharmaceutical executive with nearly 21 years of commercial business experience in various countries. He has extensive sales and marketing experience for existing businesses and startup companies. Prior to joining Iroko Pharmaceuticals, Mr. Harte was Vice President of Commercial Operations in Europe and General Manager, UK, at Novartis Vaccines. He formerly held various positions at SmithKline Beecham, and was a key member of the management teams at PowderJect and Chiron Vaccines.

Mr. Harte is a member of the UK Institute of Directors (IoD) and was the Vice-Chairman of the UK Vaccines Industry Group.

Senior Vice President, Strategy and Business Operations

Paul Hemsley joined Iroko Pharmaceuticals in July 2007, as Vice President Strategy & Portfolio Development. He has over 20 years of pharmaceuticals industry experience. Prior to Iroko, Dr. Hemsley was VP for Strategic Planning and most recently VP Marketing Excellence for Novartis (formerly Chiron) Vaccines. Before working at Chiron he was a management consultant, advising life sciences companies on commercial and R&D strategy. Earlier in his career Dr. Hemsley also worked at Glaxo Wellcome, progressing though roles of increasing responsibility including Corporate Strategy Advisor, Global Brand Manager, and Clinical Research Scientist. Dr. Hemsley received his B.Sc. in physiology and Ph.D. in neurobiology from the University of London and also holds a masters degree in business administration.

Senior Vice President, Corporate Development

Rohit Mehta has over 19 years of experience in a broad range of global business and corporate development, including licensing, M&A due diligence, joint ventures, product acquisitions, start-ups, API sourcing, early- and late-stage technology assessment, project development, and company and industry analyses.

Prior to joining Iroko Pharmaceuticals, Mr. Mehta was a principal in Jay Consulting, a firm providing business and corporate development consulting to venture capital, drug delivery, and biotechnology and pharmaceutical companies in the US and Asia. Before that, he held a number of senior- and middle-level management positions, including Vice President of Corporate Development at Dr. Reddy's Laboratories (US) and EpiCept Corporation, and as Director of Business Development at Endo Pharmaceuticals.

Mr. Mehta serves on the IRB and IBC committees at Temple University.

Vice President, Regulatory Affairs and Compliance

Steve Jensen is a senior regulatory professional with over 17 years industry experience leading U.S. and international development and post-marketing programs.

Prior to joining Iroko Pharmaceuticals, Mr. Jensen was a principal advisor and a co-founder of Laurus Regulatory Advisors, a pharma/biotech consulting firm specializing in strategic product development and commercial advertising & promotional consulting services. Prior to that, he held senior regulatory positions with SkyePharma PLC, Parexel Consulting, and Verus Pharmaceuticals both in the U.S. and Europe. Over the course of his career, Mr. Jensen has overseen the submission and successful approval of multiple NDA / ANDA products, as well a multitude of IND applications across an array of therapeutic areas.